Teva Reports Successful Phase III Trials For Asthma Drug

September 3, 2014 | Teva Pharmaceutical Industries reported that its reslizumab asthma treatment saw positive Phase III trial results. According to the company, the drug was able to prevent serious asthma attacks in two of the case studies for the Phase III trial, showing a reduction in the number of attacks by 50 to 60 percent. “The consistent results from these duplicate Phase III trials demonstrating substantial reductions in asthma exacerbations are impressive,” said Professor Mario Castro, Washington University School of Medicine, Division of Pulmonary and Critical Care Medicine and lead investigator. Teva was founded in 1901 and is currently headed by CEO Erez Vigodman.